New York, January 21, 2026, 11:55 AM EST — Regular session
- Boston Scientific shares hovered around $91 in midday trading, showing little movement.
- The FDA reported that certain AXIOS stent delivery systems have been linked to 167 serious injuries and three fatalities, advising customers to halt use and distribution immediately.
- Boston Scientific’s $14.5 billion bid for Penumbra is under the microscope as investors await the company’s results on Feb. 4.
Shares of Boston Scientific Corporation held steady, edging just above $91.20 during late morning trading in New York on Wednesday.
The stock is steady, with investors weighing a device-safety warning from U.S. regulators while watching Boston Scientific’s latest deal moves. Attention remains on the company’s planned Penumbra acquisition, sparking speculation around financing, integration challenges, and management’s upcoming statements.
Why it matters now: product alerts can quickly translate into real-world disruptions — hospitals halt orders, doctors opt for alternatives, and lawyers take note. Meanwhile, Boston Scientific is urging shareholders to consider a major acquisition that will transform its cardiovascular lineup.
The Food and Drug Administration flagged a “potentially high-risk” problem with certain AXIOS Stent and Electrocautery-Enhanced Delivery Systems. Boston Scientific has urged customers to pull these devices from use and sale. By Dec. 23, the company reported 167 serious injuries and three deaths tied to the issue, the FDA noted. The problem arises during delivery and doesn’t affect stents that were successfully implanted. U.S. Food and Drug Administration
Boston Scientific announced on Jan. 15 it will acquire Penumbra in a cash-and-stock deal that values the company at $374 per share, putting the enterprise value near $14.5 billion. Chairman and CEO Mike Mahoney described Penumbra as “a well-established company” and highlighted that the acquisition will allow Boston Scientific to “enter new, fast-growing segments within the vascular space,” according to the company’s release. Boston Scientific
Analysts mostly see the Penumbra deal as strategic, though execution risk remains. Needham’s Mike Matson called Boston Scientific “the most logical acquirer,” pointing to minimal product overlap. Stifel’s Rick Wise highlighted markets that are “high-growth but also highly competitive,” according to MedTech Dive’s recap of research notes and the deal call. MedTech Dive
Boston Scientific climbed 3.55% Tuesday, finishing at $91.20 and ending a seven-day slide. This gain came despite the overall market retreat. The stock also outperformed several major medtech rivals that day, MarketWatch noted.
The coming days remain uncertain. Should the AXIOS issue attract more attention or make providers more wary about buying, sentiment could turn negative fast. On the other hand, if the company manages to contain the fallout and investors remain confident in the Penumbra financing, the stock might steadily claw back from this month’s drop.
Boston Scientific will hold a conference call on Feb. 4 to go over its fourth-quarter earnings. Investors are waiting on that update.
